10-Q: Dynatronics Reports Q1 2025 Results: Sales Decline, Net Loss Increases Slightly

Dynatronics Corporation reported a decrease in net sales and a slight increase in net loss for the first quarter of fiscal year 2025, compared to the same period last year.

Summary

• Dynatronics Corporation's net sales for the quarter ended September 30, 2024, decreased by 18.7% to $7.602 million, compared to $9.352 million in the same quarter of the previous year.
• The company's gross profit also decreased by 14.1% to $1.981 million, representing 26.1% of net sales, compared to $2.306 million, or 24.7% of net sales, in the prior year's quarter.
• Selling, general, and administrative expenses decreased by 12.3% to $2.232 million.
• The net loss for the quarter was $367,000, compared to a net loss of $331,000 in the same quarter of the previous year.
• Net loss attributable to common stockholders was $534,000, or $0.09 per share, compared to $528,000, or $0.12 per share, in the prior year's quarter.
• The company's cash and cash equivalents and restricted cash decreased to $329,000 as of September 30, 2024, from $534,000 as of June 30, 2024.
• Working capital was $2.535 million as of September 30, 2024, compared to $2.853 million as of June 30, 2024.
• The company has a line of credit with a maximum availability of $7.5 million, with an outstanding balance of $1.89 million as of September 30, 2024.

Sentiment

Score: 4

Explanation: The document indicates a negative trend with decreased sales and increased losses, although there are some positive aspects such as reduced expenses. The overall sentiment is cautious due to the financial performance and the need to potentially raise capital.

Positives

• Gross profit as a percentage of net sales increased to 26.1%, driven by higher product margin rates in physical therapy and rehabilitation products.
• Selling, general, and administrative expenses decreased by $314,000, or 12.3%, due to reductions in salaries, benefits, sales expenses, and repairs and maintenance.
• The company believes that its cash generated from operations, current capital resources, and equity proceeds provide sufficient liquidity to fund operations for the next 12 months.

Negatives

• Net sales decreased by $1.75 million, or 18.7%, year-over-year, primarily due to reduced volume from OEM customers and decreased demand for orthopedic soft bracing products.
• Gross profit decreased by $325,000, or 14.1%, compared to the same quarter last year.
• The net loss increased by $36,000 compared to the same quarter last year.
• Cash and cash equivalents and restricted cash decreased by $205,000 during the quarter.
• Trade accounts receivable decreased by $389,000, or 11.3%, due to reduced revenue and timing of collections.
• Inventories decreased by $123,000, or 2.2%, due to adjustments in inventory management.

Risks

• The company faces uncertainties in the broader economic environment, which could affect the global supply chain, personnel costs, and customer or product mix.
• There is a risk that the company may need to raise additional funds through the sale of equity or debt securities or from credit facilities, which may not be available on satisfactory terms.
• The company operates in a rapidly evolving and unpredictable business environment that may change the timing or amount of expected future cash receipts and expenditures.
• The company's ability to realize deferred income tax assets is uncertain, requiring a full valuation allowance.

Future Outlook

The company believes that its cash generated from operations, current capital resources, and equity proceeds provide sufficient liquidity to fund operations for the next 12 months, but there is no assurance that additional funds will not be required.

Management Comments

• Management believes that the company's estimate of the allowance for credit losses is adequate based on historical experience and customer relationships.
• Management believes that the company's allowance for inventory obsolescence is adequate based on analysis of inventory, sales trends, and historical experience.

Industry Context

The company operates in the medical device industry, which is subject to economic fluctuations and changes in demand. The decrease in sales and the increase in net loss may reflect broader industry trends or specific challenges faced by the company.

Comparison to Industry Standards

• It is difficult to provide a specific comparison to industry standards without more detailed information on the company's specific market segments and competitors.
• However, the decrease in sales and increase in net loss suggest that the company may be underperforming compared to some of its peers in the medical device industry.
• Companies like DJO Global, a major player in orthopedic bracing, and Medtronic, a large medical device manufacturer, could be considered benchmarks for comparison, but their financial results would need to be analyzed in detail to provide a meaningful comparison.

Related Party Transactions

• The company leases office, manufacturing, and warehouse facilities from shareholders and entities controlled by shareholders, with combined expenses of $337,225 for the quarter ended September 30, 2024.

Stakeholder Impact

• Shareholders may be concerned about the decrease in sales and the increase in net loss.
• Employees may be affected by potential cost-cutting measures.
• Customers may be impacted by changes in product availability or pricing.
• Suppliers may be affected by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to evaluate and take action to preserve adequate liquidity.
• The company will continue to monitor the broader economic environment and its impact on the business.

Key Dates

Keywords

medical devices, physical therapy, rehabilitation, orthopedics, pain management, athletic training, net sales, gross profit, operating loss, net loss, line of credit, reverse stock split